Cigarette smoking is associated with considerable morbidity, mortality, and public health costs. Genetic factors influence both smoking initiation and nicotine dependence, but none of the genes involved have been identified. A genome scan using 451 markers was conducted to identify chromosomal regions linked to nicotine dependence in a collection of 130 families containing 343 genotyped individuals (308 nicotine-dependent) from Christchurch, New Zealand. By pairwise analysis, the best result was with marker D2S1326 which gave a lod score under heterogeneity (H-LOD) of 2.63 (P = 0.0012) and a nonparametric linkage (NPL, Z all ) score of 2.65 (P = 0.0011). To identify regions that warranted further study, rather than comparing the pairwise scores from the scan to theoretical thresholds, we compared them to an empirical baseline, found here to be H-LOD scores of 0.5 and Z all scores of 1.0. We also found a number of large ( 
Introduction
Despite substantial reductions in the prevalence of current smoking in the last 25 years, approximately one third of adults in the United States continue to smoke.
The tremendous impact of cigarette smoking on mortality and morbidity has been well chronicled. [2] [3] [4] [5] [6] In 1990, smoking was responsible for 418 690 deaths in the US compared to 125 000 for alcohol and 8100 for cocaine. 7, 8 It has now been conclusively demonstrated that: (i) a large proportion of cigarette smokers are nicotine dependent; and (ii) nicotine is more addictive than most illicit drugs. [9] [10] [11] The 1988 Surgeon General's report on cigarette smoking 10 concluded that: '(1) cigarettes and other forms of tobacco are addicting; (2) nicotine is the drug in tobacco that causes addiction; and (3) the pharmacologic and behavioral processes that determine tobacco addiction are similar to those that determine addiction to drugs such as heroin and cocaine'. The majority of smokers want to quit, but few are successful -each year 34% try, but only 3% succeed. 12 The sheer magnitude of the health problems and costs created by smoking mandates that tremendous effort should be devoted to basic research into the biological and environmental factors involved. The insight gained would then hopefully be translated quickly into practical benefits such as earlier identification of individuals at risk, and development of more effective methods for helping people to quit smoking.
Data from family, adoption, and twin studies have consistently supported a substantial genetic component to many aspects of smoking behavior. Most convincingly, a number of large-scale population-based twin studies have shown that genetic factors contribute strongly to individual differences in smoking behavior. [13] [14] [15] [16] [17] [18] Work using inbred strains of mice, notably the elegant set of experiments by Marks, Collins, and coworkers, [19] [20] [21] [22] [23] has clearly demonstrated genetic influence on inter-individual differences of a variety of related phenotypes. These include sensitivity to nicotine, nicotinic receptor density, the ability to develop tolerance, the extent of nicotine self-administration, and cross-tolerance with other substances such as alcohol.
Liability to nicotine dependence is likely to be primarily a function of specific anatomic and functional characteristics of the brain. A recent real-time functional MRI study 24 of smokers showed that intravenous injection of nicotine induced a dose-dependent increase in neuronal activity that was most pronounced in regions that comprise specific functional systems. These were primarily the cingulate cortex and frontal regions (involved in working memory, attention, motivation, mood and emotion), and the locus ceruleus (modulation of behavioral arousal) -activation of these anatomical regions is functionally consistent with the mood-elevating and anxiolytic effects often reported by cigarette smokers. In addition, limbic subcortical regions, including the nucleus accumbens, amygdala, and hypothalamus were also strongly activated. Moreover, several independent lines of evidence have demonstrated that nicotine, like other drugs of abuse such as cocaine, amphetamines and opiates, stimulates this so-called 'central dopamine reward pathway', ie activation of mesolimbic dopaminergic neurons resulting in increased energy metabolism and dopamine release in the shell of the nucleus accumbens. [25] [26] [27] It is presumed that most of the behavioral effects of nicotine are due to activation of central nicotinic acetylcholine receptors. 28 Different pentameric combinations of receptor subunits (␣ 2 through ␣ 7 , ␣ 9 , and ␤ 2 through ␤ 4 are found in brain) generate numerous receptor subtypes, each with different regional distributions and functional characteristics that remain to be well characterized. 28 Few polymorphisms in these families of genes have been described, and the roles of the receptor subtypes in mediating the effects of nicotine on neurotransmitter release are virtually unknown. 29, 30 It does appear though, that the CHRNB2 gene (located near marker D1S305 in region 1q21.3) is essential, since knockout mice 31 without the ␤ 2 subunit lack high affinity nicotine binding in brain (levels of ␣ 2 through ␣ 7 , ␤ 3 , and ␤ 4 subunits are normal). They also lack sensitivity 31 to nicotine-elicited increases in electrophysiological discharge frequency and dopamine release in striatal dopaminergic neurons, and exhibit altered responses in a behavioral paradigm thought to reflect self-administration of reinforcing substances.
Inactivation of nicotine in the liver and lung, predominantly to (S)-cotinine, is catalyzed principally by microsomal cytochrome P450 2A6 (CYP2A6). 32 There is large inter-individual variation in cotinine formation in human microsomal preparations, but it is not clear how much is due in vivo to variations in CYP2A6 levels and activity compared to other factors. 33 The gene is located in region 19q13.2, and three mutant alleles, each of which produce an inactive enzyme, have been described: 34, 35 a substitution (CYP2A6*2), a gene conversion (CYP2A6*3), and a deletion. The *2 and *3 alleles have been suggested to protect against nicotine dependence, 36 but the accuracy of the genotyping methods used has been questioned. 37 The frequency of the *2 allele was found to be 1-3% in Swedish, Spanish, and Finnish populations, 37 and therefore is probably too rare in most Caucasian populations to be a major factor in a trait as common as nicotine dependence. No other polymorphisms known to affect CYP2A6 function have been reported.
It is reasonable, therefore, to investigate whether polymorphisms in the genes involved in the regulation of neurotransmission by nicotinic acetylcholine receptors, dopaminergic transmission (eg the D4 receptor 38 ), or metabolic pathways, may contribute to individual differences in the susceptibility to smoking initiation, nicotine dependence and withdrawal symptoms. In addition, the genes that regulate the expression of such genes, or that serve to modulate the function of the protein products, are also functional candidates. A number of other candidate genes besides these also deserve consideration. 39, 40 The strategy of our research program on smoking and nicotine is to use the positional and candidate gene approaches synergistically, and to collaborate with other groups that have complementary resources and methods. The goal is to identify those genes that contribute most to susceptibility, to use this knowledge as a tool to identify and characterize in greater detail the important environmental variables, and then to explore the interactions between genes and environment. The long-term goal is to contribute to a better understanding of the variety of mechanisms, from molecular to interpersonal, that mediate smoking behavior and nicotine dependence. We report here preliminary results from one approach in the first phasea complete genome scan of an affected sib pair sample collected in Christchurch, New Zealand, and followup of the six most positive regions in a second, independent sample from Richmond, Virginia, USA.
Methods

Subjects
The subjects for this investigation were recruited and studied at two sites using nearly identical protocols. Table 1 shows some of the characteristics of the samples. The protocols were reviewed and approved by the appropriate ethical committees at each site. The first sample was recruited in Christchurch, New Zealand and was used for the complete genome scan. The second sample was recruited in Richmond, Virginia (USA) and was used for followup of regions selected because they were positive in the scan. Ascertainment was via convenience sampling and included advertisements in a wide variety of media, smoking cessation clinics, and via word-of-mouth. Inclusion criteria for a sibling pair included: the presence of lifetime nicotine dependence, current age 18 years or older, and the provision of informed consent.
Affection status
The symptoms of nicotine dependence during the period of lifetime heaviest tobacco use were assessed with an adapted version of the Fagerstrom Tolerance Questionnaire (FTQ) 41, 42 that had previously been administered to over 7000 individuals in other studies conducted by our group. 17 The FTQ is widely used in smoking research to assess nicotine dependence and consists of eight brief questions (eg how soon after you wake up do you smoke your first cigarette? and do you smoke if you are so ill that you are in bed most of the day?). Total FTQ scores range from 0-11. A substantial body of research suggests that FTQ scores are positively correlated with plasma nicotine and cotinine levels and predict unsuccessful attempts at smoking cessation. 42 Following the cutoff used by others [43] [44] [45] we defined nicotine dependence as an FTQ score greater than or equal to 7. All subjects must have reported FTQ scores of 7 or more on two separate occasions, during an initial telephone screening and then again during the study interview.
Isolation of DNA from cytology brushes DNA was obtained during direct interview by having the subjects collect buccal epithelial cells (from inside of the cheek) using standard cytology brushes 46 (Fisher Scientific, Pittsburgh, PA, USA). DNA preparation was done from four brushes per subject using the 'Instagene Purification Matrix' from Biorad Laboratories (Hercules, CA, USA) as per the protocol provided. The procedure simultaneously lyses the buccal cells, lyses the nuclei, and the majority of the non-DNA contaminants are adsorbed to the matrix, which is pelleted, leaving the chromosomal DNA free in solution. We prepare two tubes of DNA per subject, 600 l each, and made working stocks at a dilution of 1:50. We have done extensive work with DNA from brushes, and have not found the banding pattern, error rates, or 'readability' of microsatellite markers to be significantly different between DNA from brushes and DNA isolated from blood or cell lines. The percentage of samples for which most markers amplify well is about 95%. From our twin zygosity studies, MZ twins tested with 15 fluorescent microsatellite markers provided an estimate of 0.7% for the genotyping error rate.
Markers, maps and genotyping
The markers were predominantly tri-and tetra-nucleotide repeat microsatellites generated by the Cooperative Human Linkage Center (CHLC; http://www.chlc.org/), and many are from the Weber screening set, version 8.0 (http://www.marshmed.org/genetics/). Allele information, marker order, sex-averaged distances 47 were copied from the Marshfield Medical Research Center web site (http://www.marshmed.org/genetics/). Before production work, all markers were tested to confirm their amplification in multiplex PCR, lack of spurious alleles, and ease of scoring. Genomic DNA (3.5 l of a 1:50 dilution of the stock sample) per well was loaded on the bottom of a 96-well Greiner (Lake Mary, FL, USA) Thermoquick PCR plate with use of a Tecan (Research Triangle Park, NC, USA) Genesis 200 Robotic Sample Processor (RSP) and dried. The plates were stored at room temperature for up to 2 months -dried DNA produces essentially the same results as a newly prepared sample. PCR mix (3.5 l) was distributed on the side of the wells of the PCR plate by the Tecan RSP. Plates were manually tapped, put on an oscillating shaker for 10 min (380 rpm) and the wells covered with mineral oil. The final concentrations of the components of PCR reaction were: [1] [2] [3] [4] [5] , then 6 min at 72°C. Samples from up to 10 PCR plates were pooled together and mixed with formamide and dye using the Tecan RSP in the following proportions: 33% pooled PCR products, 13% ABI Tamra GS500, 53.7% formamide, 0.3% Dextran Blue, 0.025% Bromphenol Blue. The pooling and multiplexing schemes were designed in accordance with the size and color of the PCR product, and we generally loaded 10 markers per lane. The mix was denatured for 10 min at 95°C and approximately 0.4 l was stagger loaded with a Kloehn 8-syringe loader onto a 30-cm gel (6% Long Ranger acrylamide) with 96-well sharktooth comb. Gels were run on PE-ABI (PE Biosystems, Foster City, CA, USA) Model 377 DNA sequencers at 100 W (3000 V) for 2.5 h. DNA from CEPH individuals 1331-01 and 1331-02 was amplified and loaded in parallel to confirm allele sizes. Gel data files were automatically tracked and then sometimes manually adjusted using ABI GENESCAN™ software (v3.0) and scored blind to phenotype using the ABI GENOTYPER™ software (v2.0). Mendelian inheritance was checked using the program Geno (v1.1 from Marshfield Center for Medical Genetics), and sex was determined. Incompatibilities were either resolved unambiguously or the data for the entire family were discarded. We used the program RELPAIR 49 to estimate empirically the degree of genetic relationship based on multipoint analysis of 30 and then again of 95 markers in the Christchurch sample and of 45 markers in the Richmond sample.
Linkage analysis
We are unaware of any prior estimates of single-major locus models for nicotine dependence. We therefore began by assuming a penetrance in males of 60% for the highest risk and 5% for the lowest risk genotype. From a large epidemiologic sample of twins from the Virginia Twin Registry that included the FTQ, the lifetime prevalence for nicotine dependence, as defined in this report, was 24% in males and 11% in females. However, among regular smokers, the prevalence of nicotine dependence was 36% in males and 26% in females. We decided to utilize population prevalence rates, but set the penetrance in females to be 70% of that in males. Using the GENEHUNTER program 50 (v1.0) we generated pairwise lod scores under the assumption of heterogeneity (H-LODS) and nonparametric linkage (NPL Z all ) scores and their associated P values. We report only the maximum H-LOD score for each markerestimates of the recombination fractions () and proportions of families segregating the disease locus (␣) at which that maximum occurred are available on request. We report the NPL Z all statistic, which is calculated based on group-wise S all allele sharing among affecteds in sibships -for many markers in this study, the values of Z all and Z pairwise were very similar (data not shown). GENEHUNTER (v 2.0) was also used to generate multipoint H-LODs and NPL (Z all ) scores over entire chromosomes for the Christchurch sample and over the regions tested in the Richmond sample. We also applied the extensions to GENEHUNTER proposed by Kong and Cox, 51 which test the significance of observed multipoint allele sharing using the efficient score statistic distribution, as implemented in the GENEHUNTER-PLUS program. This program generates a different statistic termed Z lr , which is probably more accurate than Z all , in which the perfect data approximation can lead to overly conservative P values when there is missing information. 51, 52 However, Z lr has the property that its minimum is zero, which limits its utility in evaluating the evidence against linkage provided by the negative Z all values given by GENEHUNTER. We therefore used both programs for multipoint analysis and present both results. Allele frequencies were estimated from all independent (unrelated) individuals.
Results
Sample characteristics
A genome scan using 451 markers was conducted to identify chromosomal regions linked to nicotine dependence in a collection of 130 families containing 343 genotyped individuals (308 affected) from Christchurch, New Zealand. Six of the most positive regions were then further investigated by additional genotyping of the Christchurch sample and of an independent sample from Richmond, Virginia (91 families containing 264 genotyped individuals, 211 affected). Some descriptive statistics for the two samples are shown in Table 1 . They are similar in general composition, phenotypic characteristics, and size distribution of affected sibships. As might be expected since both samples are predominantly Caucasian (mixed European) in origin, the allele frequencies for markers tested on the Richmond sample were extremely similar to those found in Christchurch.
Maps and final marker distribution
We used the sex-averaged maps 47 from the Marshfield Medical Research Center (3655 cM total). Including estimated distances to the telomeres, the final mean intermarker distance was 7.7 cM (SD = 3.8 cM; range 0-22 cM). Over 90% of the markers contained tetranucleotide repeats, and the mean marker heterozygosity was 0.74 (SD 0.08; range 0.45-0.95).
Distribution of scores
We used the program GENEHUNTER 50 to calculate heterogeneity lod scores (H-LOD) under dominant and recessive models, and to calculate the NPL statistic Z all . The vast majority of markers must be unlinked, but each will still produce a maximum H-LOD near or at zero at large recombination fractions. The distribution of scores above 0.5, given as score (number observed) was as follows. Dominant: Ͼ2 (1), 1-2 (7) As expected, about 6% of markers gave H-LODs greater than 0.5 and 5% of Z all scores were greater than 1.0. We used these two values as the working baseline. Figure 1 shows the pairwise H-LODs, under dominant (top panel) and recessive (middle panel) models, for all 451 markers in the genome scan of the Christchurch sample (hereafter called Christchurch). Maximum HLODs (ie the largest lod score obtained at any recombination fraction and proportion of families linked) are plotted at the marker locations. The bottom panel of Figure 1 shows the pairwise nonparametric score Z all . The largest H-LOD was 2.63 (P = 0.0012) with marker D2S1326 under a dominant model, which also produced a Z all score of 2.65 (P = 0.0011). In addition to three markers on chromosome 10 (D10S2469, D10S1239, D10S677), markers D16S422, D17S2059, and D18S869 also produced Z all scores greater than 1.5.
Most positive scores
Choice of followup regions
To identify chromosomal regions that warranted follow up, we ranked the results from each of the three tests and found that multiple markers on chromosomes 2, 10, 16, 17, and 18 gave scores that were above baseline ( Figure 1 ). Flanking markers in all five regions provided additional support for linkage. Since at this stage false negatives are highly undesirable, and the highest scores in the genome scan will not necessarily identify all regions containing susceptibility genes, we examined the data more carefully.
Clustering of positive scores
Application of sib-pair methods to simulated data showed that the region around a true susceptibility locus contained a long string of consecutive positive (P Ͻ 0.05) markers. 53 In addition, by simulation it has been shown 54 that for two regions containing equal maximum peak heights, the distance over which the positive pairwise scores are observed in the presence of a gene will be longer than in the absence of one, and that longer positive regions are more likely to contain the gene of interest than shorter ones. This suggests that the longer positive regions should be given priority, but tests based on detecting this differential do not serve to definitively distinguish true signals from false. 53, 55 Our scan sample consisted primarily of affected sib pairs (132 unique, 201 total), and we expect that for false positives, the correlation between adjacent markers will extend over only relatively 'short' distances. We have not developed a good method to accurately predict the characteristics of this effect in our samples, but the scan data suggest that IBD sharing due to random fluctuation extends over large (Ͼ20 cM) regions for only a percentage of the (presumably false) positives. We found that often Z all scores Ͼ Overall in the scan, if we define a 'cluster' as three or more markers (which would cover on average only about 15 cM) each with Z all scores Ͼ0, we found few. There were eight cluster of three markers (two were on Chrs. 
Followup results from the Christchurch and Richmond samples
The pairwise H-LOD and Z all scores obtained for markers on these six chromosomes (which includes some followup markers to fill gaps), are shown for the Christchurch and Richmond samples in Table 2a -f. The corresponding nonparametric multipoint results, the Z all score from GENEHUNTER and the test statistic Z lr from GENEHUNTER-PLUS, are shown in Figure 2 . Below (P = 0.003) and Z all of 2.22 (P = 0.01). In Richmond, there is no evidence for linkage from 100-142 cM, but a cluster of six markers in a row with Z all scores Ͼ0 proximally, from 70-98 cM. Two of the four markers with Z all scores Ͼ 1.5 in Christchurch were tested in Richmond and were negative. Thus there is little overlap in the signals from the two samples. Chromosome 10 multipoint: In Christchurch, the positive region extends from 85-149 cM, with the larger peak of Z lr = 2.43 (P = 0.008) at 125 cM and a secondary peak at 105 cM. In Richmond, the maximum is Z lr = 1.21 at 75 cM, and the curve remains positive through 93 cM. Z all is strongly negative from 100-150 cM, the location of the larger peak in the Christchurch sample. More markers will be run across the length of chromosome 10 to clarify the Richmond peak location and maximum. The maximum in Christchurch is Z lr = 1.64 at 93 cM, with a broad peak between 80 and 120 cM. The maximum in Richmond is Z lr = 1.6 at 66 cM, the peak extending Overall, the Christchurch genome was 28% positive (1023 of 3655 cM). The six Christchurch (whole) chromosomes followed up were 54% positive and the seventeen that were not followed up were 18% positive. As a whole, the regions followed up (677 cM total) were 39% positive in Richmond. If one omits chromosome 4 which is 211 cM long and is clearly negative, the Richmond sample was 51% positive (244 of 481 cM). By this measure, the Richmond multipoint results resemble more closely the six followup chromosomes (39 or 51% vs 54%) than the genome as a whole (39 or 51% vs 28%) and were quite unlike the seventeen chromosomes not followed up (39 or 51% vs 18%). The Richmond sample is smaller (about 70% in both number of families and number of affecteds), so if the gene has identical effects in each, the maximum Z all should be smaller for Richmond than for Christchurch. If so, the reduced peak height should result 54 in a reduced percentage positive cM in Richmond. This not unreasonable possibility makes the relatively positive results observed in Richmond even more interesting.
Results from the Christchurch genome scan -other chromosomes Multipoint Z scores (Z all and Z lr ) for the seventeen chromosomes which were not followed up are shown in 
Discussion
To our knowledge, this is the first published report of a complete genome scan designed to detect genes that influence the risk of nicotine dependence. The goal of the scan was to identify regions that are likely to contain genes, and the goal of the followup was to distinguish between true and false signals. As we expected from the outset, we have made some progress towards these goals, but they have not been achieved. For traits in which both the phenotype and the genetic architecture are complex, it is now apparent that the relationship between the absolute values of linkage statistics (or their associated P values) and the true likelihood of a susceptibility gene being present is not straightforward. [56] [57] [58] [59] [60] [61] [62] Genome scan results from a wide variety of complex traits have shown that both highly 'significant' linkages and rapid, convincing 'replications' are uncommon. The presence of genetic heterogeneity and multiple, interacting genes each of moderate effect size, are likely to be the primary causes of the difficulty. With the sample sizes and genomic information currently available, low density genome scans for complex traits remain a crude and incomplete tool for gene identification -as a rule producing large potential target regions of debatable significance. This recurring roadblock requires that a more powerful and integrated set of tools be applied. These will include DNA microarrays and other emerging technologies, utilization of functionally annotated sequence databases, and the exploitation of the tremendous biological manipulations possible with model organismsespecially in the development of candidate gene assays and disease models. Better planning and greater attention to sample characteristics is essential, including trait-specific strategies for ascertainment-especially including access to populations with particular advantageous characteristics, gaining access to much larger sample sizes while keeping undesired increases in genetic and etiologic heterogeneity to a minimum. Phenotyping that is more standardized, detailed, and comprehensive, with the identification and validation of reliable endophenotypes will also be required. Finally, a new generation of analytical tools would be welcome, including more flexible and comprehensive tests of linkage and linkage disequilibrium that integrate multivariate, multilocus, and quantitative approaches and fully exploit their advantages, and as well as the refinement of routines for haplotype analysis capable of capitalizing on the upcoming wealth of information on human evolution.
Although the definition of nicotine dependence we used is fairly well justified, it is only one component of a larger set of interrelated phenotypes, which probably include elements of personality 17, 63 and psychopathology. 17, 64, 65 This composite phenotype is likely to be influenced by multiple, interacting genes, some of which interact bidirectionally with environmental variables. Under such a scenario, studies of polygenic traits 66 that use only a single sample of moderate power are likely to detect only genes (if they exist at all) of relatively large effect. Individual studies will probably not provide an unambiguous, coherent, and reasonably complete picture of the genetic architecture. However, careful comparison of the results from independent genome scans may enable detection and confirmation of at least some genes whose signals were not obvious previously. To facilitate this type of comparison, we have chosen to present our dataset as a work in progress, and explain in detail why in the absence of 'significant' linkage results, we still think that these regions deserve some priority in other studies. We have presented as much of the data as possible to allow for independent evaluation of strengths and weaknesses, and will provide further information upon request.
If only the most simple evaluation (ie comparison to the traditional or proposed thresholds of significance) of the data is made, then none of the putative loci are 'significant' in either sample. It would not be unexpected, therefore, if most of the signals are false. The pertinent question then becomes in the absence of any detectable susceptibility genes in either sample, how likely is it that the observed (and interrelated) patterns in the data are due to chance? For example, we would like to be able to calculate accurately how likely it is that the clusters (the pattern of consecutive Z all scores Ͼ 0) found in the Christchurch sample on chromosomes 4 (nine markers over 62 cM), 18 (16 markers over 88 cM), and 10 (15 markers over 76 cM) have all occurred by chance? In the Christchurch scan, chromosomes 2 and 10 had the two highest pairwise H-LOD scores (2.63 and 2.20 respectively) and Z all scores (2.65 and 2.22 respectively) and the greatest multipoint Z lr maximums (2.63 and 2.43 respectively). In the Richmond followup of chromosomes 2 and 10 (154 cM total), we found clusters of eight and six markers respectively. Since clusters of size six or greater occurred only three times in the 25-fold larger scan, it seems rather unlikely that the Richmond results on these two chromosomes were due to chance. Finally, using the Christchurch scan data as a benchmark, a number of different (but not independent) comparisons suggest that, when considered as a whole, the results from the Richmond sample in the six regions tested (677 cM total) are notably more positive than would be expected if the markers or the regions had been chosen at random.
On chromosome 2, markers over 82 cM were tested in both samples, and the most positive pairwise results in each are from markers that are only 2 cM apart. On chromosome 10, however, the Richmond multipoint values are quite negative at the location of the larger Christchurch peak, although there is some overlap (from 85 to 93 cM) with the secondary peak. On chromosome 16, the peaks in the two samples are located at the same position, but on chromosome 17 they are offset by about 25 cM. The poor overlap between the multipoint peaks on chromosomes 10 and 17 in the two samples is not surprising, as this has been predicted by several simulation studies. It has been shown that the size of the confidence intervals for gene location increases quite rapidly as the relative risk or the proportion of alleles shared by affected relatives decreases. 67 Even with large sample sizes, and a gene conferring a sixfold increased risk to sibs, if one confines the search to the region of maximal sharing, the gene will be missed over 60% of the time. 68 Hovatta and colleagues noted 69 considerable error in the position of the maximum lod scores, especially for sample sizes of 100 or 200 sib pairs and for the less significant findings. We have also examined this issue by simulation. 70 For example, with 200 families (each with two parents and two affected offspring), assuming 25% of families were linked, and setting an intermarker distance of 2 cM, analysis of 500 replicates showed that the GENEHUNTER multipoint peak varied markedly. The standard deviation was 25 cM, and the 95% confidence interval was 100 cM. More importantly, for a number of genes whose locations are now known (for example the MHC region and the insulin gene in type 1 diabetes 71 ), the magnitude and position of the maximum signal was routinely quite variable across studies.
The data presented are preliminary in a number of ways. First, there are more potential positives from Christchurch (chromosomes 1, 3, 8, 13 and X) to follow up. Second, we are working on higher density followups as well as completing the scan on the Richmond sample using the same marker sets. Third, we present here only the results of standard parametric and nonparametric analyses using GENEHUNTER to analyze a categorical phenotype, where individuals with FTQ scores greater than or equal to 7 are considered affected. We have done a few preliminary analyses of chromosomes 2 and 10 using the QUANTI-TATIVE (SIBS) options of GENEHUNTER (v 2.0), treating the FTQ scores and two other phenotypic measures as individual quantitative traits. The results were not an improvement over the standard methods in terms of significance levels or gene localization (data not shown). Exploratory analyses that may provide more power are planned, including multipoint quantitative, 72 multilocus 73, 74 and multivariate 75 approaches. In parallel to these two genome scans, we have begun a systematic evaluation of functional candidate genes in the nicotinic cholinergic, dopaminergic, GABAergic, and cytochrome systems, among others. We are identifying new single nucleotide polymorphisms (SNPs) by sequence alignment, direct sequencing, and other methods, and are testing multiple SNPs per gene to analyze haplotypes. Candidate gene testing is being done in parallel in the families from Christchurch and Richmond, and in a case-control study of an independent set of individuals from the Virginia Twin Study. 17 In this study, we are attempting to make some headway on the fundamental question of the probable overlap between genes contributing to smoking initiation and those contributing to nicotine dependence by contrasting three groups: lifelong non-smokers (n = 338), non-dependent regular smokers (FTQ scores 0-3; n = 258), and nicotine-dependent smokers (FTQ scores 7-11; n = 337). We are also actively accessing new families containing concordant and/or discordant sib pairs and families with available parents to be used for tests of linkage disequilibrium by TDT, and by Sib-TDT. 76, 77 Even though the linkage results presented here were not 'significant' by standard statistical criteria, they are nevertheless encouraging, especially that the Richmond sample appears to be more positive than one would expect if no susceptibility gene(s) were present. After completion of the scan of the Richmond sample, we will analyze that scan independently. We will then combine the genotype data with those from Christchurch and apply more powerful analytical tools to the combined sample. These linkage studies will be integrated with case-control and family-based association studies of functional (and eventually positional), candidate genes. We hope that this report serves to stimulate and enhance the search in independent samples for genes contributing to nicotine dependence.
